The stock has a 36-month beta value of 0.25.
The public float for NEUP is 8.15M, and at present, short sellers hold a 4.91% of that float. On December 30, 2024, the average trading volume of NEUP was 849.19K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NEUP) stock’s latest price update
The stock of Neuphoria Therapeutics Inc (NASDAQ: NEUP) has decreased by -9.44 when compared to last closing price of 4.45. Despite this, the company has experienced a 34.28% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-23 that BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited’s proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time).
NEUP’s Market Performance
Neuphoria Therapeutics Inc (NEUP) has seen a 34.28% rise in stock performance for the week, with a 18.67% gain in the past month and a -47.51% plunge in the past quarter. The volatility ratio for the week is 60.72%, and the volatility levels for the past 30 days are at 23.76% for NEUP. The simple moving average for the last 20 days is 10.41% for NEUP stock, with a simple moving average of -47.87% for the last 200 days.
Analysts’ Opinion of NEUP
Many brokerage firms have already submitted their reports for NEUP stocks, with H.C. Wainwright repeating the rating for NEUP by listing it as a “Buy.” The predicted price for NEUP in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on September 28, 2023 of the previous year 2023.
Maxim Group, on the other hand, stated in their research note that they expect to see NEUP reach a price target of $10, previously predicting the price at $7. The rating they have provided for NEUP stocks is “Buy” according to the report published on September 28th, 2023.
H.C. Wainwright gave a rating of “Buy” to NEUP, setting the target price at $54 in the report published on January 10th of the previous year.
NEUP Trading at 13.50% from the 50-Day Moving Average
After a stumble in the market that brought NEUP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.01% of loss for the given period.
Volatility was left at 23.76%, however, over the last 30 days, the volatility rate increased by 60.72%, as shares surge +12.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.52% upper at present.
During the last 5 trading sessions, NEUP rose by +34.28%, which changed the moving average for the period of 200-days by -69.47% in comparison to the 20-day moving average, which settled at $3.65. In addition, Neuphoria Therapeutics Inc saw -77.31% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NEUP
Equity return is now at value -59.91, with -42.49 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.30.
Conclusion
To sum up, Neuphoria Therapeutics Inc (NEUP) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
